LEXINGTON, Mass.--(BUSINESS WIRE)--May 25, 2021--
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present at two upcoming investor conferences:
Jefferies Virtual Healthcare Conference on June 2, 2021 at 2:30 p.m. EDT
Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021 at 8:00 a.m. EDT
A live webcast of the presentations can be accessed on the investors section of Frequency’s website, investors.frequencytx.com. A replay of the presentations will be posted on the Frequency website following the event.
About Frequency Therapeutics
Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The Company’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The Company’s lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function. FX-322 is being evaluated in multiple ongoing clinical studies in patients with sensorineural hearing loss. The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including in a pre-clinical program in multiple sclerosis.
Headquartered in Lexington, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham, Massachusetts Institute of Technology, The Scripps Research Institute and Cambridge Enterprises Limited. For more information, visit www.frequencytx.com and follow Frequency on Twitter @Frequencytx.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005105/en/
Carlo Tanzi, Ph.D.
Kendall Investor Relations
Source: Frequency Therapeutics, Inc.